Emerging Treatment Options for Adolescents and Young Adults with Relapsed or Refractory Lymphoma

Nmazuo W. Ozuah and Ann S. LaCasce

Department of Pediatric Oncology, Dana Farber Cancer Institute, USA
Department of Medical Oncology, Dana Farber Cancer Institute,

^*Correspondance to: Ann S. LaCasce 

 PDF  Full Text Case Report | Open Access

Abstract:

Lymphomas are amongst the most common cancers in Adolescents and Young Adults (AYA). Despite favorable outcomes with upfront therapy, survival in patients with relapsed or refractory disease remains poor. Promising therapeutic agents are emerging, including monoclonal antibodies, antibody drug conjugates, immune checkpoint inhibitors, cytotoxic T-cell therapies, small molecule pathway inhibitors and epigenetic modulators. Clinical trials of novel agents have predominantly enrolled older adult patients. Furthermore, research relating to the biology of lymphomas has focused predominately on younger children and older adults. Future investigation should concentrate on the biology of lymphomas in AYAs and improving their participation in clinical trials.

Keywords:

Cite the Article:

Ozuah NW, LaCasce AS. Emerging Treatment Options for Adolescents and Young Adults with Relapsed or Refractory Lymphoma. Clin Oncol. 2016; 1: 1141.